Outcomes for APBI With Strut-Based Brachytherapy: 596 Patients With 39-Month Median Follow-Up

(grade 0 vs grade 1 vs grade 2/3) compared to a V105 > 10% (p Z 0.09 and 0.03, respectively). The mean DoS was 22 cm (range 16-30 cm), with 22% and 3% of patients having a DoS greater than 25 cm and 28 cm, respectively. The mean BV was 1523 cc (range 299-3279 cc), with 19% and 5% having a BV greater than 2000 cc and 2500 cc, respectively. Neither a larger DoS nor a larger BV correlated with an inability to achieve a V105 10% (p Z 0.37 and p Z 0.13, respectively). Neither DoS nor BV predicted for worse acute toxicity, chronic toxicity, or cosmesis. Conclusions: Minimizing the V110 and V115 and limiting the V105 to 10% are useful dosimetric objectives to achieve excellent or good cosmesis following H-WBI. Acceptable toxicity and excellent cosmesis is achievable in women with large DoS or BV, provided techniques to maximize dose homogeneity are employed. Author Disclosure: R.V. Hymas: None. M.S. Jawad: None. V.S. Mangona: None. L. Zamdborg: None. J.L. Wobb: None. A. Pietron: None. M. Wallace: None. P.Y. Chen: None. I.S. Grills: None. D.S. Brabbins: None. J.T. Dilworth: None.